The Treatment of Advanced Colorectal Cancer

Publication
Article
Special ReportsGastrointestinal Cancers (Issue 1)
Volume 1
Issue 1

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses the treatment of patients with advanced colorectal cancer.

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses the treatment of patients with advanced colorectal cancer (CRC).

Read more about the treatment of CRC andthe need for fullRASmutational analyses > >

Articles in this issue
The Identification of Molecular Subtypes of Gastric Cancer
The Identification of Molecular Subtypes of Gastric Cancer
Ramucirumab Combo Increases Survival in Gastric Cancer
Ramucirumab Combo Increases Survival in Gastric Cancer
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Data
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Data
New Standard of Neoadjuvant Care for Rectal Cancer Established
New Standard of Neoadjuvant Care for Rectal Cancer Established
Reducing the Risk of Relapse in Patients With Pancreatic Cancer
Reducing the Risk of Relapse in Patients With Pancreatic Cancer
Vismodegib Demonstrates Activity in Advanced Pancreatic Cancer
Vismodegib Demonstrates Activity in Advanced Pancreatic Cancer
The Treatment of Advanced Colorectal Cancer
The Treatment of Advanced Colorectal Cancer
Studies Emphasize Need for Full <em>RAS</em> Mutational Analyses in the Management of mCRC
Studies Emphasize Need for Full <em>RAS</em> Mutational Analyses in the Management of mCRC
TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCC
TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCC
Recent Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Related Content
Invikafusp Alfa Shows Potential in PD-1 Refractory Solid Tumors

Invikafusp Alfa Shows Potential in PD-1 Refractory Solid Tumors

Jordyn Sava
November 21st 2024
Article

Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally associated malignancies.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Jonah Feldman
November 15th 2024
Article

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

Fellow's Perspective: Patient Case of Newly Diagnosed Multiple Myeloma

Fellow's Perspective: Patient Case of Newly Diagnosed Multiple Myeloma

Targeted Oncology Staff
November 13th 2024
Article

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with transplant-eligible multiple myeloma and the data behind their decisions.

Read More

Nivolumab-Chemotherapy Combo Boosts PFS in cHL, Poised for Standard Use

Nivolumab-Chemotherapy Combo Boosts PFS in cHL, Poised for Standard Use

Morgan Bayer
November 12th 2024
Article

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, particularly benefiting patients 60 and older.

Read More